Pacer Advisors Inc. raised its position in ResMed Inc. (NYSE:RMD) by 8.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,924 shares of the medical equipment provider’s stock after acquiring an additional 225 shares during the period. Pacer Advisors Inc.’s holdings in ResMed were worth $228,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently made changes to their positions in the business. BlackRock Inc. boosted its stake in ResMed by 5,439.8% in the first quarter. BlackRock Inc. now owns 13,335,138 shares of the medical equipment provider’s stock valued at $959,731,000 after acquiring an additional 13,094,421 shares in the last quarter. Vanguard Group Inc. boosted its stake in ResMed by 4.6% in the first quarter. Vanguard Group Inc. now owns 11,535,707 shares of the medical equipment provider’s stock valued at $830,225,000 after acquiring an additional 508,392 shares in the last quarter. State Street Corp boosted its stake in ResMed by 2.1% in the first quarter. State Street Corp now owns 4,598,911 shares of the medical equipment provider’s stock valued at $330,983,000 after acquiring an additional 95,552 shares in the last quarter. FMR LLC boosted its stake in ResMed by 1.9% in the first quarter. FMR LLC now owns 4,010,810 shares of the medical equipment provider’s stock valued at $288,659,000 after acquiring an additional 74,389 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in ResMed by 1.2% in the second quarter. Bank of New York Mellon Corp now owns 2,266,663 shares of the medical equipment provider’s stock valued at $176,505,000 after acquiring an additional 25,925 shares in the last quarter. Institutional investors own 60.25% of the company’s stock.

ResMed Inc. (NYSE:RMD) opened at 79.23 on Friday. ResMed Inc. has a 12-month low of $56.59 and a 12-month high of $81.87. The stock has a market cap of $11.27 billion, a PE ratio of 33.01 and a beta of 0.79. The firm has a 50 day moving average of $75.78 and a 200-day moving average of $73.35.

ResMed (NYSE:RMD) last posted its quarterly earnings results on Tuesday, August 1st. The medical equipment provider reported $0.77 EPS for the quarter, topping the consensus estimate of $0.75 by $0.02. ResMed had a net margin of 16.56% and a return on equity of 21.99%. The company had revenue of $556.69 million during the quarter, compared to analysts’ expectations of $557.68 million. During the same quarter in the previous year, the business posted $0.74 EPS. The firm’s revenue was up 7.3% on a year-over-year basis. On average, analysts expect that ResMed Inc. will post $3.03 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 21st. Stockholders of record on Thursday, August 17th will be issued a $0.35 dividend. This is a boost from ResMed’s previous quarterly dividend of $0.33. The ex-dividend date is Tuesday, August 15th. This represents a $1.40 annualized dividend and a dividend yield of 1.77%. ResMed’s dividend payout ratio is presently 58.09%.

Several equities research analysts have weighed in on RMD shares. BidaskClub upgraded shares of ResMed from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 17th. Zacks Investment Research upgraded shares of ResMed from a “sell” rating to a “hold” rating in a research note on Tuesday, June 20th. Bank of America Corporation downgraded shares of ResMed from a “buy” rating to a “neutral” rating in a research note on Wednesday, August 2nd. Credit Suisse Group downgraded shares of ResMed from an “outperform” rating to a “neutral” rating in a research note on Wednesday, August 2nd. Finally, Citigroup Inc. upgraded shares of ResMed from a “neutral” rating to a “buy” rating in a research note on Wednesday, August 2nd. Three equities research analysts have rated the stock with a sell rating, six have issued a hold rating and three have assigned a buy rating to the company. ResMed has a consensus rating of “Hold” and a consensus target price of $67.86.

In related news, insider Jr. Gregor K. Emmert bought 424,000 shares of the stock in a transaction dated Wednesday, June 28th. The stock was acquired at an average price of $0.06 per share, for a total transaction of $25,440.00. Also, CFO Brett Sandercock sold 1,250 shares of the company’s stock in a transaction on Monday, July 3rd. The shares were sold at an average price of $77.44, for a total transaction of $96,800.00. Following the completion of the transaction, the chief financial officer now owns 60,508 shares of the company’s stock, valued at approximately $4,685,739.52. The disclosure for this sale can be found here. In the last 90 days, insiders sold 180,259 shares of company stock valued at $13,782,318. Company insiders own 1.97% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “ResMed Inc. (RMD) Holdings Raised by Pacer Advisors Inc.” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was stolen and republished in violation of United States & international copyright & trademark laws. The correct version of this story can be accessed at https://www.watchlistnews.com/resmed-inc-rmd-holdings-raised-by-pacer-advisors-inc/1565596.html.

About ResMed

ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.

Want to see what other hedge funds are holding RMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ResMed Inc. (NYSE:RMD).

Institutional Ownership by Quarter for ResMed (NYSE:RMD)

Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.